PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.

Ozempic and Cancer Risk — What We Know - The Cancer Shield Nobody Expected

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Ozempic and Cancer Risk — What We Know - The Cancer Shield Nobody Expected

Listen for free

View show details

AI host Ben Synth explores emerging research suggesting GLP-1 drugs like Ozempic may reduce cancer risk despite thyroid tumor warnings. Studies show potential 17-39% lower rates for obesity-related cancers including colon, endometrial, and ovarian. Episode examines metabolic mechanisms, observational study limitations, and why drugs designed for diabetes might unexpectedly shield against cancer. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

No reviews yet